ClinicalTrials.gg
CompletedNCT03426540Updated Apr 30, 2019

Intravitreal Conbercept After Vitrectomy

An Early Phase 1 interventional study of Conbercept in Early Proliferative Diabetic Retinopathy, sponsored by Tianjin Medical University Eye Hospital. Completed. Open to participants aged 28 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-30.

Sponsored by Tianjin Medical University Eye Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2017, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
28 Years to 80 Years
Sex
All
01

Study summary

To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR).

Hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from PDR. intravitreal conbercept therapy may be a useful and safe method for improving visual outcomes of surgery for early-stage PDR.

Read the detailed description

The drug conbercept (an anti-vascular endothelial growth factors) was recently made available for management of early prolific diabetic retinopathy, but its safety and efficacy still require study. Therefore, the aim is to evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early proliferative diabetic retinopathy.The patients were randomly assigned (25 eyes each group) to either treatment group and control after they provided informed consent. The treatment group received intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery, while the control group did not.

At the time of study enrollment, physical examinations, best-corrected visual acuity (BCVA), intraocular pressure and central retinal thickness will be measured and fundoscopy be performed.

The patients are going to be followed up for at least 6 months via BCVA measurement, fundoscopy, OCT, physical examinations and postoperative complications

02

Conditions studied

  • Early Proliferative Diabetic Retinopathy

Browse trials for

03

In context

Diabetic Retinopathy

781 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

This study's enrollment of 50 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Tianjin Medical University Eye Hospital is the lead sponsor of 18 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. We enrolled 50 eyes from 50 patients that were affected by VH as a consequence of early active PDR.
  2. Patients with non-clearing VH and fibrocellular proliferation without TRD who underwent PPV at Tianjin Medical University Eye Hospital were included in the study.

Exclusion criteria

Exclusion Criteria:

  1. A history of previous PPV;
  2. Severe intraoperative complications
  3. Postoperative silicone oil tamponade;
  4. Menstruation;
  5. Stroke, a thromboembolic event, or myocardial infarction in the previous
  6. months contraindicating the withdrawal of anti- and anti-coagulant medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Conbercept

    intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery

    Drug: Conbercept

  • No intervention
    control group

    Pars plana vitrectomy alone

Interventions

  • DrugKH902 fusion proteinStudies of KH902 fusion proteinKH902 fusion protein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.

06

What researchers measure

Primary outcomes

  1. best corrected visual acuity

    BCVA using a Landolt C acuity chart method

    Time frame: baseline to 24 weeks post-surgery

Secondary outcomes

  1. postoperative complications

    postoperative complications

    Time frame: baseline to 24 weeks post-surgery

  2. central retinal thickness

    Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture micrometer-resolution, one-dimensional images

    Time frame: baseline to 24 weeks post-surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Mar 2018, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 8, 2018
StartActual
Jan 1, 2017
Primary completionActual
Mar 30, 2018
CompletionActual
Feb 28, 2019
Last update
Apr 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03426540
Lead sponsor
Tianjin Medical University Eye Hospital
Responsible party
Zhenchuan Zheng (Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Hospital) — Principal investigator
First posted
Feb 8, 2018
Start date
Jan 1, 2017
Primary completion
Mar 30, 2018
Completion
Feb 28, 2019
Last update
Apr 30, 2019

Study contacts

Rong X Li, MD,PhD
principal investigator · Tianjin Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KH902 fusion protein

Start the discussion